Analysts Offer Predictions for Adagene FY2026 Earnings

Key Points

• HC Wainwright projects Adagene will report FY2026 EPS of ($0.37) vs the consensus of ($0.60), and provided multi-year EPS estimates through FY2030 (FY2027: ($0.44); FY2028: ($0.74); FY2029: ($1.13); FY2030: ($0.92)).
• Analyst sentiment is mixed-to-positive with an average rating of "Buy" and a $8.00 consensus target; two firms rate it Strong Buy, two Buy and one Sell, while Guggenheim recently raised its target to $10 and kept a Buy rating.
• Adagene beat quarterly EPS expectations (reported ($0.04) vs. consensus ($0.28)) but missed revenue estimates materially ($3.84M actual vs. $17.50M expected); shares opened at $4.00 and trade in a 12-month range of $1.30–$4.75.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Adagene in a research report issued on Tuesday, April 7th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.37) per share for the year. The consensus estimate for Adagene's current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Adagene's FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.74) EPS, FY2029 earnings at ($1.13) EPS and FY2030 earnings at ($0.92) EPS.

ADAG has been the subject of several other research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adagene in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Adagene to a "hold" rating in a research note on Saturday, March 21st. Finally, Guggenheim boosted their target price on shares of Adagene from $9.00 to $10.00 and gave the company a "buy" rating in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $8.00.

Adagene Stock Performance

Shares of NASDAQ:ADAG opened at $4.00 on Thursday. The company has a fifty day simple moving average of $3.40 and a 200 day simple moving average of $2.41. Adagene has a 12-month low of $1.30 and a 12-month high of $4.75.

Adagene (NASDAQ:ADAG - Get Free Report) last issued its quarterly earnings results on Wednesday, April 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.24. The company had revenue of $3.84 million during the quarter, compared to the consensus estimate of $17.50 million.

Institutional Trading of Adagene

Institutional investors have recently added to or reduced their stakes in the business. Marex Group plc bought a new stake in Adagene during the second quarter valued at $47,000. SmartHarvest Portfolios LLC bought a new position in shares of Adagene during the fourth quarter worth about $73,000. Citadel Advisors LLC bought a new position in shares of Adagene during the third quarter worth about $80,000. Gordian Capital Singapore Pte Ltd grew its position in shares of Adagene by 101.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 48,342 shares of the company's stock worth $96,000 after acquiring an additional 24,342 shares during the last quarter. Finally, Fifth Lane Capital LP grew its position in shares of Adagene by 427.3% during the fourth quarter. Fifth Lane Capital LP now owns 145,000 shares of the company's stock worth $274,000 after acquiring an additional 117,500 shares during the last quarter. Institutional investors own 9.51% of the company's stock.

Adagene Company Profile

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.